Enzymatica is hoping to shake up the OTC cold and flu category across North America and Asia by introducing its virus-blocking mouth spray ColdZyme.
Enzymatica Plots Entry To North America And Asia
The Swedish firm is plotting the path towards launching its ColdZyme virus-blocking spray in China and Japan, while efforts are also underway to find a partner for the North American market.
More from Strategy
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.
More from Earnings
• By
Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.
• By
CEO says firm’s “three clear imperatives” to drive cash and “total shareholder return” comprise its “three S” plan. Perrigo’s net sales for the quarter down 1.6% to $1.14bn and for the year down 6.1% to $4.37bn.
• By
Full-year revenues up 14% to $732m and Q4 up 5% to $186m. Communications VP Dan Dischner says results came from “resilience of our portfolio, driven by contributions from key products such as Primatene Mist and the integration of Baqsimi into our expanding diabetes franchise.”